An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation in adult patients.

Trial Profile

An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation in adult patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Inolimomab (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Sponsors EUSA Pharma
  • Most Recent Events

    • 15 Mar 2018 According to an ElsaLys Biotech Media Release, a poster summarising the safety profile results to be presented at the 44th congress of the European Society for Blood and Marrow Transplantation.
    • 15 Mar 2018 Results published in an ElsaLys Biotech Media Release
    • 15 Aug 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top